2. Cancer
  3. Cancer Targeted Therapy

Cancer Targeted Therapy

Cancer targeted therapy is the foundation of precision medicine; it uses drugs or other substances to target specific genes and proteins that control cancer cells’ growth, division and spreading. Compared to traditional chemotherapy drugs, targeted-drugs can specifically act on cancer cells with high efficacy without damaging normal cells. Drugs used in cancer targeted therapy mainly includes small molecules and macromolecules (e.g., monoclonal antibodies), which can target cancer cells and constituents in the tumor microenvironment to activate the immune system. Anti-angiogenesis drugs, such as those targeting vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), transforming growth factor (TGF)-α, TGF-β, Tumor necrosis factor (TNF)-α, and platelet-derived endothelial growth factor (PDGFR) inhibit the proliferation and metastasis of cancer cells. In recent years, the proportion of antibody drugs in cancer treatment has gradually become prominent. Antibody-drug conjugates (ADCs) are a new type of targeted drugs that are composed of monoclonal antibody, cytotoxic drug and linker. ADCs can deliver drugs to tumor cells and minimize the toxicity to normal tissues. Proteolysis-targeting chimera (PROTAC) is a useful technology for targeted protein degradation. PROTAC exploits the ubiquitin-proteasome system and forms a ternary complex with a hijacked E3 ubiquitin ligase and target protein, leading to polyubiquitination and degradation of the target protein.

Targeted therapy is a useful strategy in treatment of cancer either alone or in combination with standard chemotherapy. At present, targeted therapy has proved significant clinical success in the treatment of many types of cancer, including breast cancer, colorectal cancer, leukemia, ovarian cancer and lung cancer.

Cancer Targeted Therapy Related Products (44025):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-R00248
    hsa-miR-132-3p mimic
    hsa-miR-132-3p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.
    hsa-miR-132-3p mimic
  • HY-169120
    FKB04 108979-07-3 99.98%
    FKB04 is a telomeric repeat binding factor 2 (TRF2) inhibitor that exerts its antitumor activity by disrupting the telomere maintenance mechanism in liver cancer cells, leading to T-loop defects, telomere shortening, and cellular senescence. Additionally, FKB04 can inhibit tumor growth in a human liver cancer xenograft mouse model (with Huh-7 cells implanted in BALB/c mice). FKB04 can be used in liver cancer research.
    FKB04
  • HY-P10709
    CREKA peptide 847058-45-1 99.80%
    CREKA peptide is a selective non-covalent binding agent targeting fibrin, type IV collagen, and fibronectin, often used as a targeting ligand to modify delivery carriers. CREKA peptide specifically recognizes fibrin, fibronectin, and type IV collagen that are excessively deposited in the tumor microenvironment or fibrotic tissue, mediating the targeted accumulation of the carrier at the lesion site and promoting drug internalization into target cells (such as cancer cells and activated hepatic stellate cells). CREKA peptide can enhance targeted delivery efficiency, increase drug concentration at the lesion site, and reduce systemic side effects.
    CREKA peptide
  • HY-140013
    Fmoc-NH-PEG1-C2-acid 1654740-73-4 99.83%
    Fmoc-NH-PEG1-C2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
    Fmoc-NH-PEG1-C2-acid
  • HY-173156
    UNC10013 99.90%
    UNC10013 is an inhibitor targeting the triple Tudor domain (3TD) of SETDB1. UNC10013 covalently binds to Cys385 of SETDB1 3TD, acts as a negative allosteric modulator of the methyltransferase domain of SETDB1, reduces the level of Akt methylation mediated by SETDB1, and blocks Tyr308 phosphorylation of Akt. UNC10013 is applicable to cancer-related research.
    UNC10013
  • HY-13703A
    Nimustine hydrochloride 55661-38-6 99.00%
    Nimustine hydrochloride (ACNU) is the hydrochloride salt form of Nimustine (HY-13703). Nimustine hydrochloride is an alkylating agent, which induces DNA double-strand breaks (DSBs) and inter-strand crosslinks (ICLs), thereby activating the DNA damage response (DDR) signaling pathway. Nimustine hydrochloride activates p38 MAPK/JNK signaling pathway, and exhibits antitumor activity.
    Nimustine hydrochloride
  • HY-119966
    CCT036477 305372-78-5 99.42%
    CCT036477 is a Wnt/β-catenin pathway inhibitor. CCT036477 blocks transcription at β-catenin without altering its levels. CCT036477 inhibits proliferation of various cancer cells, development of embryos, and expression of Wnt target genes (PPARδ, Cyclin D1, TCF4, and ID2).
    CCT036477
  • HY-110077
    API-1 36707-00-3 99.62%
    API-1 is a potent selective Akt/PKB inhibitor that reduces the level of phosphorylated Akt (IC50 = 0.8 μM). API-1 binds to the PH domain and inhibits Akt membrane translocation. API-1 induces c-FLIP degradation. API-1 reduces cell proliferation and induces apoptosis. API-1 decreases tumor growth in mouse xenograft model.
    API-1
  • HY-10421
    Tyrosine kinase inhibitor 1021950-26-4 99.88%
    Tyrosine kinase inhibitor is a potent tyrosine kinase inhibitor.
    Tyrosine kinase inhibitor
  • HY-N0093
    Ancitabine hydrochloride 10212-25-6 99.83%
    Ancitabine hydrochloride is a cytarabine derivative that inhibits viral replication. Ancitabine hydrochloride blocks vaccinia virus DNA replication, the progression of viral protein synthesis from early to late stages, and one-step growth of vaccinia virus. Ancitabine hydrochloride is applicable to research related to vaccinia virus infection, leukemia, human cytomegalovirus infection and colorectal cancer.
    Ancitabine hydrochloride
  • HY-129942
    S-(1-Hydroxy-2-methylpropan-2-yl) methanesulfonothioate 2127875-65-2
    S-(1-Hydroxy-2-methylpropan-2-yl) methanesulfonothioate is a glutathione cleavable ADC linker used for the antibody-drug conjugates (ADCs) and refers to the Alkyl-Chain composition. S-(1-Hydroxy-2-methylpropan-2-yl) methanesulfonothioate is the linker portions of the molecules employed for mAb attachment purposes.
    S-(1-Hydroxy-2-methylpropan-2-yl) methanesulfonothioate
  • HY-177880
    2-MSP-5-HA-VC-PAB-MMAE 2878440-80-1 98.59%
    2-MSP-5-HA-VC-PAB-MMAE (Compound B-1) is a Drug-Linker Conjugates for ADC. 2-MSP-5-HA-VC-PAB-MMAE consists of the ADC Cytotoxin Monomethyl auristatin E (HY-15162) and a linker 2-MSP-5-HA-VC-PAB-OH (HY-177905). 2-MSP-5-HA-VC-PAB-MMAE can be used for synthesis of ADCs.
    2-MSP-5-HA-VC-PAB-MMAE
  • HY-127002
    Squarunkin A 2101958-02-3 99.49%
    Squarunkin A is a potent and selective UNC119-cargo interaction inhibitor, interrupting the UNC119A-myristoylated Src N-terminal peptide interaction (IC50=10 nM). Squarunkin A interferes with the activation of Src kinase in cells.
    Squarunkin A
  • HY-133063
    Fmoc-NH-PEG8-CH2COOH 868594-52-9 99.41%
    Fmoc-NH-PEG8-CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-NH-PEG8-CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
    Fmoc-NH-PEG8-CH2COOH
  • HY-162361
    HDAC1-IN-7 794552-20-8 99.97%
    HDAC1-IN-7 (compound 9) is potent HDAC1 inhibitor, with the IC50 of 0.957 mM.
    HDAC1-IN-7
  • HY-B1204R
    Histamine (Standard) 51-45-6
    Histamine (Standard) is the analytical standard of Histamine (HY-B1204). This product is intended for research and analytical applications. Histamine is the agonist for histamine receptor and a vasodilator. Histamine is an organic nitrogen compound that participates in local immune responses, regulates intestinal physiological functions, and acts as a neurotransmitter. Histamine affects p38 MAPK/Akt signaling pathway, exhibits antitumor, antioxidant and anti-inflammatory activities. Histamine can be used in the research of acute myeloid leukemia, malignant melanoma, and renal cell carcinoma.
    Histamine (Standard)
  • HY-108549
    clasto-Lactacystin β-lactone 154226-60-5 99.9%
    Clasto-Lactacystin β-lactone, a natural active metabolite of lactacystin, which is a metabolite of Streptomyces, acts as an irreversible 20S proteasome inhibitor.
    clasto-Lactacystin β-lactone
  • HY-158764
    PROTAC BET Degrader-12 3068070-16-3 98.10%
    PROTAC BET Degrader-12 (Compound 8b) is a PROTAC degrader for bromodomain and extra-terminal domain (BET)-containing proteins, which degrades the BRD3 and BRD4 in a DCAF11-dependent manner. PROTAC BET Degrader-12 inhibits cell viability of KBM7 with a DC50 of 305.2 nM. (Pink: ligand for target protein (+)-JQ-1 (HY-13030); Black: linker (HY-159077); Blue: ligand for E3 ligase (HY-159076))
    PROTAC BET Degrader-12
  • HY-100218C
    (1R,3R)-RSL3 1219810-15-7 99.05%
    (1R,3R)-RSL3 is an isomer of RSL3 (HY-100218A). RSL3 ((1S,3R)-RSL3) is an inhibitor of glutathione peroxidase 4 (GPX4) (ferroptosis activator), reduces the expression of GPX4 protein, and induces ferroptotic death of head and neck cancer cell. RSL3 increases the expression of p62 and Nrf2 and inactivates Keap1 in HN3-rslR cells.
    (1R,3R)-RSL3
  • HY-13615
    Folate-FITC 583037-91-6
    Folate-FITC (EC-17) is a folate receptor alpha (FRα) targeting contrast agent with fluorescent properties in the visible light spectrum. The Folate-FITC maximum excitation and emission wavelengths are 490 nm and 520 nm, respectively.
    Folate-FITC